ArticleBMC medical ethics2026
Consent in flux: when brain‑computer interface embodiment undermines informed consent.
Article in BMC medical ethics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundIn March 2026, China approved the first invasive brain‑computer interface (BCI) for clinical use globally. While this milestone accelerates neurotechnology translation, it exposes a neglected ethical problem: in some long-term invasive BCI cases, participants who initially consent to later device explantation may subsequently develop functional dependence on, and phenomenological incorporation of, the device. This paper examines whether such post-implantation integration can weaken the continuing moral authority of initial consent to explantation.
methodsThis paper provides a normative analysis grounded in established bioethics concepts. We draw on theories of extended cognition and transformative experience, integrate findings from qualitative empirical studies of BCI user phenomenology, and engage with the neurorights discourse and Chinese regulatory developments. The analysis focuses on the moral authority of initial consent where long-term device integration may alter the participant's embodied agency, with particular attention to the implications for interpreting the right to withdraw from research.
resultsTransformative experience alone is not sufficient to distinguish implantable BCIs from other medical interventions that may also alter self-understanding. The distinctive diachronic consent problem arises when ex ante experiential ignorance is combined with extended cognition, embodied agency, functional dependence, and the possibility that explantation would remove a device experienced as part of the user's agential system. We identify a specific governance gap in China's current ethical guidelines and propose three interlocking reforms: adopting a dynamic consent model with periodic re‑consent encounters, establishing ongoing ethical review for implanted participants, and decoupling withdrawal from research from consent to explantation. An ethical algorithm to guide explantation decisions is presented.
conclusionsInformed consent for long-term invasive BCI use should be reconceptualised as an ongoing process where there is evidence of functional dependence or phenomenological incorporation. Initial consent remains important, but it should not be treated as conclusively authorising later explantation without post-integration reassessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.